To Be Discontinued Injection Oncology
Pemetrexed Disodium Injectio · 336 days since initial FDA posting
Brand: PEMETREXED
FDA lists Pemetrexed Disodium Injectio as To Be Discontinued (Sandoz Inc.).
No availability text on this FDA row.
Pemetrexed Disodium Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Pemetrexed Disodium Injection
- Manufacturer
- Sandoz Inc.
- Dosage Form
- Injection
- Presentation
- Pemetrexed Disodium, Injection, 500 mg/20 mL (NDC 0781-3519-90)
- Package NDC
- 0781-3519-90
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Oct 10, 2025
- Last Updated
- Oct 10, 2025
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Pemetrexed Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.